Abacavir induces loading of novel self-peptides into HLA-B*57
The role of microRNAs in HIV-1 pathogenesis and therapy
A literature review of reporting standards of HIV progression models
Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings
Antiretroviral therapy interruptions result in loss of protective humoral immunity to neoantigens in HIV-infected individuals
A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis
Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir
Prevalence and risk factors associated with pulmonary hypertension in HIV-infected patients on regular follow-up
Response to antiretroviral therapy
Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals
Viral load monitoring of antiretroviral therapy, cohort viral load and HIV transmission in Southern Africa
Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America
The prognostic value of baseline CD4+ cell count beyond 6 months of antiretroviral therapy in HIV-positive patients in a resource-limited setting
Recovery of HIV service provision post-earthquake
Number of missed doses
The role of individual-based models in understanding the potential impact of antiretroviral therapy for prevention
Genetic variability at the TREX1 locus is not associated with natural resistance to HIV-1 infection
Undiagnosed HIV prevalence based on nontargeted screening in emergency departments
Beneficial course of two cases of HIV-associated multicentric Castleman disease treated with HIV antiretroviral therapy
HIV neutralizing antibody titer during structured treatment interruption of highly active antiretroviral therapy
Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170)
Novel clinical trial designs and HIV-1 RNA assessments with end-point and real-time PCR tests
Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir